Live Breaking News & Updates on Alucenex Life Sciences Inc 39 Halucenex

Stay updated with breaking news from Alucenex life sciences inc 39 halucenex . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

The wholly-owned Creso Pharma subsidiary is currently conducting clinical trials of its synthetic psilocybin formulation as treatment for mental health conditions NEDLANDS, Australia, Feb. 9, 2023 /PRNewswire/ Creso Pharma Limited(ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. ('Halucenex'), is exploring opportunities to register its synthetic psilocybin formulation for the Australian market following recent regulatory changes. The Therapeutic Goods Administration (TGA), the medicine and therapeutic regulatory agency of the Australian Government, recently announced that the medical use of MDMA and psilocybin will be reclassified from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines). This ruling allows authorized psychiatrists to prescribe medicines containing MDMA and psilocybin for the treatment of certain mental health conditions as of July 1, 2023. Based in Winds ....

Switzerland General , Western Australia , Creso Pharma , Halucenex Life Sciences Inc , Creso Pharma Limited , Therapeutic Goods Administration , Pharma Limited , Creso Pharma , Life Sciences , Australian Government , Nova Scotia , Psilocybin Supplier , Health Canada , Special Access , Managing Director William , Good Manufacturing Practice , The Wholly Owned Creso Pharma Subsidiary Is Currently Conducting Clinical Trials Of Its Synthetic Psilocybin Formulation As Treatment For Mental Health Conditions Nedlands , Feb 9 , 023 Prnewswire Creso Pharma Limited Asx Cph , Ra 1x8 39 Creso Pharma Is Pleased To Announce Its Wholly Owned Psychedelics Subsidiary , Alucenex Life Sciences Inc 39 Halucenex , S Exploring Opportunities To Register Its Synthetic Psilocybin Formulation For The Australian Market Following Recent Regulatory Changes Therapeutic Goods Administration Tga , He Medicine And Therapeutic Regulatory Agency Of The Australian Government , Ecently Announced That The Medical Use Of Mdma And Psilocybin Will Be Reclassified From Schedule 9 Prohibited Substances To 8 Controlled Medicines This Ruling Allows Authorized Psychiatrists Prescribe Containing For Treatment Certain Mental Health Conditions As July 1 , 023 Based In Windsor , Nova Scotia ,